Project/Area Number |
18K07806
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
Research Institution | Saitama Children's Medical Center |
Principal Investigator |
Sato Satoshi 埼玉県立小児医療センター (臨床研究部), 感染免疫科, 医長 (60385028)
|
Co-Investigator(Kenkyū-buntansha) |
菅沼 栄介 埼玉県立小児医療センター (臨床研究部), 感染免疫科, 副部長 (60408010)
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Keywords | 皮膚筋炎 / 若年性皮膚筋炎 / 間質性肺炎 / MDA5 / 抗MDA5抗体 / 疾患モデル作成 / マクロファージ / サイトカイン |
Outline of Final Research Achievements |
Anti-MDA5 antibody is associated with interstitial lung disease (ILD) in patients with juvenile dermatomyositis (JDM). Methods: MRL/Mp-lpr/lpr mice. They received pristane IP. And recombinant human MDA5 protein (rMDA5) was instilled. Results: H&E staining of lung from WT mouse compared with lung from a MRL/lpr mouse treated with pristane + rMDA5 protein showing mild thickening of the alveolar septa despite the alveolar hemorrhage. And perivascular lymphocytes infiltrate in a MRL/lpr mouse rather than a WT mouse treated with pristane + rMDA5 protein. The Lymphocyte infiltrations around alveolar macrophages was more prominent in MRL/lpr mouse treated with pristane + rMDA5 protein than other mouse. Conclusions: These results suggest that lung involvements such as the alveolar hemorrhage, are caused by pristeine and rMDA5 prtotein in the pathogenesis of interstitial pneumonia.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究ではMDA5が肺組織において炎症を惹起、増悪させる因子働くことが推察された。炎症細胞の浸潤とともに肺組織の破壊が起こっている。一方で自己免疫応答の機序の検討は本研究では充分に行うことができていない。今後の課題と考える。 現在も抗MDA5抗体関連お皮膚筋炎、間質性肺炎の病態は解明されていないため本研究のデータをもとに更なる検討を行うことで病態の解明がさらに進み、治療に結びつく可能性がある。
|